These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20881645)

  • 1. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
    Gitlitz BJ; Moon J; Glisson BS; Reimers HJ; Bury MJ; Floyd JD; Schulz TK; Sundaram PK; Ho C; Gandara DR
    J Thorac Oncol; 2010 Nov; 5(11):1835-40. PubMed ID: 20881645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Lara PN; Moon J; Redman MW; Semrad TJ; Kelly K; Allen JW; Gitlitz BJ; Mack PC; Gandara DR
    J Thorac Oncol; 2015 Jan; 10(1):110-5. PubMed ID: 25490004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
    Wakelee HA; Lee JW; Hanna NH; Traynor AM; Carbone DP; Schiller JH
    J Thorac Oncol; 2012 Oct; 7(10):1574-82. PubMed ID: 22982658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
    Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
    Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
    Miller AA; Pang H; Hodgson L; Ramnath N; Otterson GA; Kelley MJ; Kratzke RA; Vokes EE;
    J Thorac Oncol; 2010 Mar; 5(3):380-4. PubMed ID: 20087228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
    Matei D; Sill MW; Lankes HA; DeGeest K; Bristow RE; Mutch D; Yamada SD; Cohn D; Calvert V; Farley J; Petricoin EF; Birrer MJ
    J Clin Oncol; 2011 Jan; 29(1):69-75. PubMed ID: 21098323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
    Lara PN; Chansky K; Davies AM; Franklin WA; Gumerlock PH; Guaglianone PP; Atkins JN; Farneth N; Mack PC; Crowley JJ; Gandara DR
    J Thorac Oncol; 2006 Nov; 1(9):996-1001. PubMed ID: 17409985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
    Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
    Chi KN; Ellard SL; Hotte SJ; Czaykowski P; Moore M; Ruether JD; Schell AJ; Taylor S; Hansen C; Gauthier I; Walsh W; Seymour L
    Ann Oncol; 2008 Apr; 19(4):746-51. PubMed ID: 18056648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
    Williamson SK; Moon J; Huang CH; Guaglianone PP; LeBlanc M; Wolf GT; Urba SG
    J Clin Oncol; 2010 Jul; 28(20):3330-5. PubMed ID: 20498388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
    Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
    Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
    Srkalovic G; Hussein MA; Hoering A; Zonder JA; Popplewell LL; Trivedi H; Mazzoni S; Sexton R; Orlowski RZ; Barlogie B
    Cancer Med; 2014 Oct; 3(5):1275-83. PubMed ID: 24913924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
    Bellmunt J; Maroto-Rey P; Trigo JM; Carles J; Guillem V; López-Martín JA; Antón-Torres A; Urruticoechea L
    Clin Transl Oncol; 2010 Jul; 12(7):503-8. PubMed ID: 20615828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
    Nimeiri HS; Oza AM; Morgan RJ; Huo D; Elit L; Knost JA; Wade JL; Agamah E; Vokes EE; Fleming GF
    Gynecol Oncol; 2010 Apr; 117(1):37-40. PubMed ID: 20117828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
    Sridhar SS; Winquist E; Eisen A; Hotte SJ; McWhirter E; Tannock IF; Mukherjee SD; Wang L; Blattler C; Wright JJ; Moore MJ
    Invest New Drugs; 2011 Oct; 29(5):1045-9. PubMed ID: 20191303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
    Chen L; Shen Y; Luo Q; Yu Y; Lu H; Zhu R
    Thyroid; 2011 Feb; 21(2):119-24. PubMed ID: 21186953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
    Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Schwandt A; von Gruenigen VE; Wenham RM; Frasure H; Eaton S; Fusco N; Fu P; Wright JJ; Dowlati A; Waggoner S
    Invest New Drugs; 2014 Aug; 32(4):729-38. PubMed ID: 24619298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.